Connect your AI

Protagonist Therapeutics PTGX Price / sales

Price / sales at other companies

Bristol-Myers SquibbBMY

2.6×-0.1×

Eli LillyLLY

11.4×-3.8×

AmgenAMGN

5.1×+0.2×

IncyteINCY

3.5×+0.8×

AbbVieABBV

6.1×-0.3×

Spyre Therapeutics, Inc.SYRE

1,993×+1,970×

Other financials

Income statement

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

Market cap$7.26B+127%

Enterprise value$7.07B+130%

Profitability

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Calculated from Protagonist Therapeutics’s reported figures.

market cap/total revenue=90.8×

Based on the most recent quarter.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Protagonist Therapeutics's price / sales?: Protagonist Therapeutics (PTGX) reported price / sales of 90.8× in Q1 2026.
How has Protagonist Therapeutics's price / sales changed year-over-year?: Protagonist Therapeutics's price / sales increased by 535.7% year-over-year, from 14.3× to 90.8×.
What is the long-term trend for Protagonist Therapeutics's price / sales?: Over 4 years (2021 to 2025), Protagonist Therapeutics's price / sales has grown at a 18.8% compound annual growth rate (CAGR), from 59.7× to 118.7×.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.